Information from the abstract
Abstract Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) protects millions of African children, yet the contribution of each drug to preventive efficacy remains unclear. We pooled individual-level data on drug concentrations and malaria infection in 934 children from Uganda (NCT05323721), Mozambique (NCT05186363), and Burkina Faso (NCT05478954). The primary outcome was malaria infection by day 28, and the secondary outcome was the day 28 qPCR cycle threshold value. From natural variation in drug exposure, desethylamodiaquine, the active amodiaquine metabolite, was the primary determinant of malaria infection (OR 0.55, 95% CI 0.44–0.68 per standard deviation increase in log concentration). Children with low day 28 desethylamodiaquine exposure (
Why this record is monitored
This record has an Impact Signal of 81/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Malaria Research and Control · Travel-related health issues · Hemoglobinopathies and Related Disorders
Thai researcher and institutional participation
Chayanin Sararat · Kanokon Suwannasin · Stéphane Proux · Urairat Koesukwiwat · Stije J. Leopold · Arjen M. Dondorp · Joel Tärning · Mallika Imwong · François Henry Nosten · Nicholas John White · Mahidol University · Mahidol Oxford Tropical Medicine Research Unit · Shoklo Malaria Research Unit
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.